Business Description
TCM Biotech International Corp
NAICS : 325412
SIC : 2836
ISIN : TW0004169008
Description
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.08 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 2.64 | |||||
| Interest Coverage | 8.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 8.87 | |||||
| Beneish M-Score | -2.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.8 | |||||
| 3-Year EBITDA Growth Rate | -5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year Book Growth Rate | 20.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.55 | |||||
| 9-Day RSI | 48.17 | |||||
| 14-Day RSI | 49.87 | |||||
| 6-1 Month Momentum % | -10.05 | |||||
| 12-1 Month Momentum % | 5.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.95 | |||||
| Quick Ratio | 4.03 | |||||
| Cash Ratio | 2.54 | |||||
| Days Inventory | 130.47 | |||||
| Days Sales Outstanding | 82.59 | |||||
| Days Payable | 50.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.06 | |||||
| Dividend Payout Ratio | 0.1 | |||||
| 3-Year Dividend Growth Rate | -55 | |||||
| Forward Dividend Yield % | 0.06 | |||||
| 5-Year Yield-on-Cost % | 0.06 | |||||
| 3-Year Average Share Buyback Ratio | -5.4 | |||||
| Shareholder Yield % | 0.76 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.52 | |||||
| Operating Margin % | 2.3 | |||||
| Net Margin % | 1.92 | |||||
| FCF Margin % | -4.38 | |||||
| ROE % | 2.61 | |||||
| ROA % | 1.83 | |||||
| ROIC % | 2.9 | |||||
| ROC (Joel Greenblatt) % | 4.34 | |||||
| ROCE % | 3.1 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 155.71 | |||||
| PE Ratio without NRI | 155.71 | |||||
| Shiller PE Ratio | 118.7 | |||||
| PEG Ratio | 259.52 | |||||
| PS Ratio | 2.99 | |||||
| PB Ratio | 3.06 | |||||
| Price-to-Tangible-Book | 3.12 | |||||
| EV-to-EBIT | 114.41 | |||||
| EV-to-EBITDA | 60.76 | |||||
| EV-to-Revenue | 2.93 | |||||
| EV-to-FCF | -68.24 | |||||
| Price-to-Projected-FCF | 5.3 | |||||
| Price-to-Median-PS-Value | 1.21 | |||||
| Price-to-Graham-Number | 4.65 | |||||
| Price-to-Net-Current-Asset-Value | 4.51 | |||||
| Price-to-Net-Cash | 13.63 | |||||
| Earnings Yield (Greenblatt) % | 0.88 | |||||
| FCF Yield % | -1.33 | |||||
| Forward Rate of Return (Yacktman) % | 0.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TCM Biotech International Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 969.619 | ||
| EPS (TTM) (NT$) | 0.35 | ||
| Beta | 0.08 | ||
| Volatility % | 34.94 | ||
| 14-Day RSI | 49.87 | ||
| 14-Day ATR (NT$) | 1.798093 | ||
| 20-Day SMA (NT$) | 54.15 | ||
| 12-1 Month Momentum % | 5.66 | ||
| 52-Week Range (NT$) | 49.333059 - 68.507795 | ||
| Shares Outstanding (Mil) | 59.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TCM Biotech International Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TCM Biotech International Corp Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
TCM Biotech International Corp Frequently Asked Questions
What is TCM Biotech International Corp(ROCO:4169)'s stock price today?
The current price of ROCO:4169 is NT$54.50. The 52 week high of ROCO:4169 is NT$68.51 and 52 week low is NT$49.33.
When is next earnings date of TCM Biotech International Corp(ROCO:4169)?
The next earnings date of TCM Biotech International Corp(ROCO:4169) is .
Does TCM Biotech International Corp(ROCO:4169) pay dividends? If so, how much?
The Dividend Yield %  of TCM Biotech International Corp(ROCO:4169) is 0.06% (As of Today), Highest Dividend Payout Ratio of TCM Biotech International Corp(ROCO:4169) was 9.05. The lowest was 0.05. And the median was 0.73. The  Forward Dividend Yield % of TCM Biotech International Corp(ROCO:4169) is 0.06%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers